Rice Hall James & Associates LLC Has $3.76 Million Stock Position in Haemonetics Co. (NYSE:HAE)

Rice Hall James & Associates LLC lessened its stake in shares of Haemonetics Co. (NYSE:HAE) by 1.3% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 46,727 shares of the medical instruments supplier’s stock after selling 604 shares during the quarter. Rice Hall James & Associates LLC’s holdings in Haemonetics were worth $3,756,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of HAE. Capital Research Global Investors grew its stake in Haemonetics by 2.3% during the 1st quarter. Capital Research Global Investors now owns 6,674,751 shares of the medical instruments supplier’s stock valued at $569,690,000 after acquiring an additional 151,183 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in Haemonetics by 6.3% during the second quarter. Dimensional Fund Advisors LP now owns 978,735 shares of the medical instruments supplier’s stock valued at $80,972,000 after purchasing an additional 57,665 shares during the last quarter. Thrivent Financial for Lutherans grew its stake in Haemonetics by 6,573.6% in the second quarter. Thrivent Financial for Lutherans now owns 849,350 shares of the medical instruments supplier’s stock valued at $70,267,000 after purchasing an additional 836,623 shares in the last quarter. Boston Trust Walden Corp increased its position in Haemonetics by 13.8% in the 3rd quarter. Boston Trust Walden Corp now owns 809,608 shares of the medical instruments supplier’s stock worth $65,076,000 after purchasing an additional 98,019 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC raised its stake in shares of Haemonetics by 75.9% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 795,381 shares of the medical instruments supplier’s stock worth $63,933,000 after purchasing an additional 343,214 shares in the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

Analyst Ratings Changes

HAE has been the subject of several recent research reports. JMP Securities reissued a “market outperform” rating and issued a $125.00 price target on shares of Haemonetics in a research note on Tuesday, August 13th. Barrington Research reissued an “outperform” rating and issued a $108.00 target price on shares of Haemonetics in a research report on Monday, September 23rd. BTIG Research initiated coverage on shares of Haemonetics in a report on Tuesday, September 10th. They set a “buy” rating and a $112.00 price target on the stock. Citigroup decreased their price objective on shares of Haemonetics from $94.00 to $85.00 and set a “neutral” rating for the company in a report on Thursday, August 22nd. Finally, Bank of America assumed coverage on Haemonetics in a research report on Wednesday, September 11th. They set a “neutral” rating and a $85.00 target price for the company. Three research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $106.14.

Haemonetics Stock Performance

Shares of NYSE HAE opened at $71.47 on Friday. Haemonetics Co. has a 12 month low of $70.25 and a 12 month high of $97.97. The company has a market cap of $3.66 billion, a P/E ratio of 32.05, a P/E/G ratio of 1.13 and a beta of 0.30. The business’s 50 day moving average is $75.46 and its two-hundred day moving average is $82.77. The company has a quick ratio of 2.33, a current ratio of 3.76 and a debt-to-equity ratio of 1.35.

Haemonetics (NYSE:HAE) last issued its quarterly earnings results on Thursday, August 8th. The medical instruments supplier reported $1.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.03 by ($0.01). The firm had revenue of $336.17 million for the quarter, compared to the consensus estimate of $335.08 million. Haemonetics had a net margin of 8.61% and a return on equity of 21.86%. The company’s revenue was up 8.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.05 earnings per share. On average, equities analysts expect that Haemonetics Co. will post 4.57 EPS for the current year.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.